Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
JERREL L YAKEL · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2024 · $1,719,113 — The Viral Vector Core facility currently offers support for production, purification, titering, and validation of twelve types of viruses: Adenovirus, Adenoassociated virus (AAV), coronaviruses (229E, OC43, NL63, and MHV), Herpes Simplex Virus (HSV), Influenza A, lentiviruses including human immunod…
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,212,338 — Based on our understanding of spike- or envelope-based mechanisms of humoral evasion, we are working to design envelope-based immunogens with these evading mechanisms disabled. Such modified immunogens with weakened defenses may elicit more broadly neutralizing antibodies. We have also devised prote…
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $427,403 — Though COVID-19 has been less disruptive than it used to be during the earlier waves of the pandemic, it has not been eradicated. Variants of the causative SARS-CoV-2 virus continue to emerge and evade neutralization by antibodies elicited by vaccination or natural infection of early variants. In th…
Tongqing Zhou · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $284,935 — The SARS-CoV-2 spike is the basis of 1st-generation FDA-approved COVID-19 vaccines. We anticipate the immunogenicity from wild-type or "2P"-stabilized spikes may not be optimal and are currently working to improve. In specific, we and others are working to define spike-based mechanisms by which SAR…
Rosemarie Mason · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $17,731 — We have isolated multiple SARS-CoV-2-specific monoclonal antibodies (mAbs) from SARS-CoV-2 convalescent donors from study VRC200. More than 25 mAbs isolated and characterized were neutralizing against SARS-CoV-2 with several mAbs showing cross-neutralization of multiple variants of concern (VOC) as …
Cheng Cheng · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $2,325,099 — During the past year, we have created and tested new vaccine candidates, including envelope proteins (Env) and fusion peptides (FP) displayed on nanoparticles as protein immunogens or mRNA vaccines. In addition, we have continued our work testing different methods and routes of administration as wel…
Chen-Hsiang Shen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $258,129 — An understanding of the serum responses of virus-infected individuals and vaccinees is critical for the development of effective vaccines against HIV-1, SARS-CoV-2 and other viral pathogens. Perhaps the most important biological aspect of a serum response is its neutralizing activity, with a close s…
Wei Zheng · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2024 · $2,200,000 — In collaboration with NIH and external academic and industry researchers, we have carried out assay development and performed drug repurposing screens for multiple projects across a range of therapeutic areas, including COVID-19, rare genetic disorders and rare drug resistant cancers. DISEASE MO…
WALTHER H MOTHES · YALE UNIVERSITY · 2024 · $822,106 — Summary The COVID19 pandemic may take 1-3 years and only fully subside once we reach herd immunity. Given the high mortality of COVID19, it is of critical importance to reach herd immunity through a vaccine. The viral spike glycoprotein (S) is central to our efforts for developing an effective vacci…
James C. Gumbart · GEORGIA INSTITUTE OF TECHNOLOGY · 2024 · $65,484 — Project summary The cloud module proposed here is focused on applying machine learning (ML) methods for the analysis of large datasets generated from molecular dynamics (MD) simulations of biomolecules. ML has become a common set of tools used in many areas of scientific research, albeit still with …
Adam Lauring · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $1,728,873 — Project Summary – Project 1 (Virus) Respiratory viruses impose a significant public health burden, in large part due to their rapid evolution and ability to evade host immunity. Influenza, COVID-19, and now RSV infection, are all vaccine-preventable diseases, yet our current system of genomic survei…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $253,500 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $1,037,822 — The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-last…
Taia Wang · STANFORD UNIVERSITY · 2024 · $347,463 — PROJECT SUMMARY lgG perform immunomodulatory signaling via lgG Fe-Fey receptor (FcyR) interactions that trigger different effector functions according to the balance of activating to inhibitory (A/I) signals. Non-neutralizing, FcyR- mediated effector functions can be critical for optimal protecti…
Christopher O'Neil Barnes · STANFORD UNIVERSITY · 2024 · $347,463 — PROJECT SUMMARY Human respiratory viruses not only contribute to substantial morbidity and mortality worldwide but also pose a massive pandemic threat. This broad range of viruses includes human coronavirus (hCoVs), influenza A, and human metapneumoviruses (HMPV). Vaccines are among the most powe…
Jodi A Hadden-Perilla · UNIVERSITY OF DELAWARE · 2024 · $175,873 — The hepatitis B virus (HBV) capsid is a promising therapeutic target that could contribute to the elimination of viral hepatitis as a major public health threat. The capsid is an icosahedral shell that assembles from 120 copies of homodimeric core protein (Cp). Small molecules currently being explor…
GREGORY C IPPOLITO · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $136,800 — Abstract Research Core C will be integral to the examination of serological antibody repertoires in COVID-19 study subjects as well as in convalescent plasmas obtained from survivors. Core C will employ a set of unique experimental techniques including a proteomic methodology (Ig-seq) for the identi…
Andrew S Neish · EMORY UNIVERSITY · 2024 · $88,878 — Abstract: The proposed Immune Monitoring Core (IMC; Core 2) has been designed to provide a unified, comprehensive, and centralized service to provide the U54 investigators with efficient and reproducible high-throughput analysis of antibody responses to SARS-CoV-2, including binding, functional char…
Jonathan R. Lai · WASHINGTON UNIVERSITY · 2024 · $4,622,541 — SUMMARY Alphaviruses are mosquito-transmitted viruses that cause severe disease in humans. The genus is divided into two groups: Arthritogenic viruses cause arthralgia and musculoskeletal disease that can persist for years after infection, and encephalitic viruses infect the brain and can cause long…
Kartik Chandran · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $2,708,082 — Viruses interact with and hijack a vast array of cellular molecules and pathways to facilitate their multiplication and spread, while also reprograming infected cells to release pathogenic viral factors (‘viral toxins’) that could be independently targeted with vaccines and therapeutics to reduce di…